Giant wins ArgiNox account

Share this article:

ArgiNox Pharmaceuticals, of Menlo Park, Ca named Giant Creative Strategy as the agency of record for their lead compound, tilarginine acetate. Tilarginine acetate is currently being studied in clinical trials for the treatment of cardiogenic shock. Giant will work with ArgiNox to develop an integrated scientific market preparation campaign, as well as naming and all branding and promotional materials for the product's impending launch.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.